Charakterisierung des antiviralen und möglichen entzündungshemmenden Wirkmechanismus von ProCluster® wahrend Influenza Virus bzw. SARS-CoV-2 Infektion
Circulating viruses such as influenza A viruses or coronaviruses (e.g. the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2)) continue to pose a global public health burden. In general, influenza A viruses and coronaviruses have pandemic potential. The development of efficient vaccines is time-consuming and specific antiviral treatment strategies are rare. Repurposing of substances that are already in clinical use for other diseases is a promising alternative for treating infections. Pharmaceutical substances that inhibit virus-supporting cellular factors or excessive immune reactions or resolve inflammatory processes are of particular interest. Initial studies indicate that ProCluster®, a local anesthetic with anti-inflammatory properties, has an inhibitory effect on both, influenza A virus and SARS-CoV-2 proliferation and spread in vitro. Within the present project, funded by the EUROPEAN FUND FOR REGIONAL DEVELOPMENT - EUROPE FOR THURINGIA, the regulation of the antiviral and possible anti-inflammatory effect of ProCluster® and ProCluster®-containing products will be investigated in more detail during influenza A virus or SARS-CoV- 2 infection in vitro, in cooperation with the inflamed pharma GmbH Jena. Basic knowledge of the molecular effects of test substances is mandatory in order to be able to assess their potential for later possible use during infections.